Access to Prescription Digital Therapeutics Act of 2023

Access to Prescription Digital Therapeutics Act of 2023 (S. 723/H.R. 1458) - To create a benefit category under Medicare and Medicaid allowing for the coverage of prescription digital therapeutics Medicaid VBPs for Patients Act (H.R. 2666) - To codify the existing Medicaid "multiple best price" rule related to value-based purchasing arrangements for drug therapies in Medicaid programs, to expand the use of value-based arrangements to drugs covered under Medicaid administered in an inpatient setting, and to make technical changes to pharmaceutical manufacturer report requirements to CMS related to these changes. Equitable Community Access to Pharmacy Services Act (H.R. 1770) - To make permanent certain emergency authorizations from the COVID-19 public health emergency related to pharmacist-provided care for COVID-19, RSV, and influenza (such as testing and immunization) and to allow reimbursement for these services under Medicare Part B. Also to automatically implement these authorizations for future public health emergencies declared under either the Public Health Service Act or the PREP Act.

Client expense: $100,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S 723/HR 1458 - Access to Prescription Digital Therapeutics Act HR 8816 - American Medical Innovation and Investment Act of 2024

Client expense: $2,760,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 4189/S.2016, CONNECT for Health Act of 2023 H.R. 4093, Remote Opioid Monitoring Act of 2023 H.R. 824, Telehealth Benefit Expansion for Workers Act of 2023 H.R.1843/S.1001, Telehealth Expansion Act of 2023 H.R. 3875, Expanded Telehealth Access Act H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023 H.R. 7623, Telehealth Modernization Act of 2024 H.R. 7856, PREVENT DIABETES Act S. 4094, PREVENT DIABETES Act General issues related to federal regulation of health technology - artificial intelligence, digital therapeutics

Client expense: $1,050,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Medicare and Medicaid reimbursement for digital therapeutics and guidance from CMS regarding Medicare and Medicaid reimbursement for digital therapeutics under existing benefit categories. Specifically, H.R 1458/S. 723 Access to Prescription Digital Therapeutics Act of 2023 and H.R. 8816, the American Medical Innovation and Investment Act of 2024.

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act (H.R. 4818/S.2407) The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)

Client expense: $850,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Issues related to prescription drug pricing and value Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax Issues related to Intellectual Property Issues related to Inflation Reduction Act The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)

Client expense: $850,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Access to Prescription Digital Therapeutics Act of 2023 (H.R. 1458/S. 723) American Medical Innovation and Investment Act (H.R. 8816)

Client expense: Not reported · Firm income: Not reported

Issues related to managed care pharmacists; H.R. 1458/S.723 - Access to Prescription Digital Therapeutics Act of 2023; H.R. 2666/S. 4204 - the Medicaid VBPs for Patients (MVP).

Client expense: Not reported · Firm income: $70,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S 723/HR 1458 - Access to Prescription Digital Therapeutics Act HR 8816 - American Medical Innovation and Investment Act of 2024

Client expense: $2,710,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.1458/S.723

Client expense: $25,221 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.1458/S.723

Client expense: $25,221 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S723/HR1458 - Access to Prescription Digital Therapeutics Act HR8816 - American Medical Innovation and Investment Act of 2024 PBM Transparency and Reform S1542/HR6283 - Delinking Revenue from Unfair Gouging (DRUG) Act HR2880 - Protecting Patients Against PBM Abuses Act HR5378 - Lower Costs More Transparency Act 340B Reform HR8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net (ACCESS) Act

Client expense: $1,070,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Access to Prescription Digital Therapeutics Act of 2023 (S. 723/H.R. 1458) - To create a benefit category under Medicare and Medicaid allowing for the coverage of prescription digital therapeutics Medicaid VBPs for Patients Act (H.R. 2666) - To codify the existing Medicaid "multiple best price" rule related to value-based purchasing arrangements for drug therapies in Medicaid programs, to expand the use of value-based arrangements to drugs covered under Medicaid administered in an inpatient setting, and to make technical changes to pharmaceutical manufacturer report requirements to CMS related to these changes. Equitable Community Access to Pharmacy Services Act (H.R. 1770) - To make permanent certain emergency authorizations from the COVID-19 public health emergency related to pharmacist-provided care for COVID-19, RSV, and influenza (such as testing and immunization) and to allow reimbursement for these services under Medicare Part B. Also to automatically implement these authorizations for future public health emergencies declared under either the Public Health Service Act or the PREP Act.

Client expense: $100,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Access to Prescription Digital Therapeutics Act of 2023 (S. 723/H.R. 1458) - To create a benefit category under Medicare and Medicaid allowing for the coverage of prescription digital therapeutics Medicaid VBPs for Patients Act (H.R. 2666) - To codify the existing Medicaid "multiple best price" rule related to value-based purchasing arrangements for drug therapies in Medicaid programs, to expand the use of value-based arrangements to drugs covered under Medicaid administered in an inpatient setting, and to make technical changes to pharmaceutical manufacturer report requirements to CMS related to these changes. Equitable Community Access to Pharmacy Services Act (H.R. 1770) - To make permanent certain emergency authorizations from the COVID-19 public health emergency related to pharmacist-provided care for COVID-19, RSV, and influenza (such as testing and immunization) and to allow reimbursement for these services under Medicare Part B. Also to automatically implement these authorizations for future public health emergencies declared under either the Public Health Service Act or the PREP Act.

Client expense: $100,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act (H.R. 4818/S.2407) The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)

Client expense: $1,180,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Issues related to prescription drug pricing and value Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax Issues related to Intellectual Property Issues related to Inflation Reduction Act The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)

Client expense: $1,180,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.1458/S.723

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.1458/S.723

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S723/HR1458 - Access to Prescription Digital Therapeutics Act HR8816 - American Medical Innovation and Investment Act of 2024 PBM Transparency and Reform S1542/HR6283 - Delinking Revenue from Unfair Gouging (DRUG) Act HR2880 - Protecting Patients Against PBM Abuses Act HR5378 - Lower Costs More Transparency Act 340B Reform HR8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net (ACCESS) Act

Client expense: $970,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 723 Access to Prescription Drug Therapeutics Act Medicare & Medicaid coverage and payment issues, regulatory and payment issues, IRA implementation

Client expense: Not reported · Firm income: $70,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 4189/S.2016, CONNECT for Health Act of 2023 H.R. 4093, Remote Opioid Monitoring Act of 2023 H.R. 824, Telehealth Benefit Expansion for Workers Act of 2023 H.R.1843/S.1001, Telehealth Expansion Act of 2023 H.R. 3875, Expanded Telehealth Access Act H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023 H.R. 7623, Telehealth Modernization Act of 2024 H.R. 7856, PREVENT DIABETES Act S. 4094, PREVENT DIABETES Act General issues related to federal regulation of health technology - artificial intelligence, digital therapeutics

Client expense: $1,110,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

American Medical Innovation and Investment Act (H.R. 8816) Section 6 requiring CMS to issue guidance on coverage/reimbursement of prescription digital therapeutics under Medicare Part B and asa supplemental benefit to an individual enrolled under a Medicare Advantage plan. Legislative efforts to require CMS to issue guidance to state Medicaid Directors regarding coverage of PDTs underMedicaid and the State Childrens Health Insurance Program. Access to Prescription Digital Therapeutics Act (H.R. 1458/S. 723) to establish Medicare/Medicaid benefit categories for PDTs. Matters related to the adoption of and reimbursement for digital health technologies.

Client expense: Not reported · Firm income: Not reported

American Medical Innovation and Investment Act (H.R. 8816) Section 6 requiring CMS to issue guidance on coverage/reimbursement of prescription digital therapeutics under Medicare Part B and asa supplemental benefit to an individual enrolled under a Medicare Advantage plan. Legislative efforts to require CMS to issue guidance to state Medicaid Directors regarding coverage of PDTs underMedicaid and the State Childrens Health Insurance Program. Access to Prescription Digital Therapeutics Act (H.R. 1458/S. 723) to establish Medicare/Medicaid benefit categories for PDTs. Matters related to the adoption of and reimbursement for digital health technologies.

Client expense: Not reported · Firm income: Not reported

Medicare and Medicaid reimbursement for digital therapeutics and guidance from CMS regarding Medicare and Medicaid reimbursement for digital therapeutics under existing benefit categories. Specifically, H.R 1458/S. 723 Access to Prescription Digital Therapeutics Act of 2023 and H.R. 8816, the American Medical Innovation and Investment Act of 2024.

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to managed care pharmacists; S.723/H.R.1458 - Access to Prescription Digital Therapeutics Act of 2023; H.R.2666/S.4204 - the Medicaid VBPs for Patients (MVP).

Client expense: Not reported · Firm income: $70,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R 1458/S. 723 Access to Prescription Digital Therapeutics Act of 2023

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Medicare and Medicaid coverage for digital therapeutics. Specifically: H.R 1458/S. 723 Access to Prescription Digital Therapeutics Act of 2023. Other legislation improving access to digital therapeutics, for example, streamlining and clarifying Food and Drug Administration approval.

Client expense: Not reported · Firm income: Not reported

H.R.1458/S.723

Client expense: $28,069 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.1458/S.723

Client expense: $28,069 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act (H.R. 4818/S.2407) The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)

Client expense: $1,030,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Issues related to prescription drug pricing and value Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax Issues related to Intellectual Property Issues related to Inflation Reduction Act The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)

Client expense: $1,030,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 4189/S.2016, CONNECT for Health Act of 2023 H.R. 4093, Remote Opioid Monitoring Act of 2023 H.R. 824, Telehealth Benefit Expansion for Workers Act of 2023 H.R.1843/S.1001, Telehealth Expansion Act of 2023 H.R. 3875, Expanded Telehealth Access Act H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023 H.R. 7623, Telehealth Modernization Act of 2024 H.R. 7856, PREVENT DIABETES Act S. 4094, PREVENT DIABETES Act General issues related to federal regulation of health technology - artificial intelligence, digital therapeutics

Client expense: $1,800,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S. 723 Access to Prescription Drug Therapeutics Act Medicare & Medicaid coverage and payment issues, regulatory and payment issues, IRA implementation

Client expense: Not reported · Firm income: $70,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Access to Prescription Digital Therapeutics Act of 2023 (S. 723/H.R. 1458) - To create a benefit category under Medicare and Medicaid allowing for the coverage of prescription digital therapeutics Medicaid VBPs for Patients Act (H.R. 2666) - To codify the existing Medicaid "multiple best price" rule related to value-based purchasing arrangements for drug therapies in Medicaid programs, to expand the use of value-based arrangements to drugs covered under Medicaid administered in an inpatient setting, and to make technical changes to pharmaceutical manufacturer report requirements to CMS related to these changes. Equitable Community Access to Pharmacy Services Act (H.R. 1770) - To make permanent certain emergency authorizations from the COVID-19 public health emergency related to pharmacist-provided care for COVID-19, RSV, and influenza (such as testing and immunization) and to allow reimbursement for these services under Medicare Part B. Also to automatically implement these authorizations for future public health emergencies declared under either the Public Health Service Act or the PREP Act.

Client expense: $240,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Access to Prescription Digital Therapeutics Act of 2023 (S. 723/H.R. 1458) - To create a benefit category under Medicare and Medicaid allowing for the coverage of prescription digital therapeutics Medicaid VBPs for Patients Act (H.R. 2666) - To codify the existing Medicaid "multiple best price" rule related to value-based purchasing arrangements for drug therapies in Medicaid programs, to expand the use of value-based arrangements to drugs covered under Medicaid administered in an inpatient setting, and to make technical changes to pharmaceutical manufacturer report requirements to CMS related to these changes. Equitable Community Access to Pharmacy Services Act (H.R. 1770) - To make permanent certain emergency authorizations from the COVID-19 public health emergency related to pharmacist-provided care for COVID-19, RSV, and influenza (such as testing and immunization) and to allow reimbursement for these services under Medicare Part B. Also to automatically implement these authorizations for future public health emergencies declared under either the Public Health Service Act or the PREP Act.

Client expense: $240,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues related to managed care pharmacists; S.723/H.R.1458 - Access to Prescription Digital Therapeutics Act of 2023; H.R.2666 - the Medicaid VBPs for Patients (MVP).

Client expense: Not reported · Firm income: $70,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Access to Prescription Digital Therapeutics Act of 2023 (S. 723/H.R. 1458) - To create a benefit category under Medicare and Medicaid allowing for the coverage of prescription digital therapeutics Medicaid VBPs for Patients Act (H.R. 2666) - To codify the existing Medicaid "multiple best price" rule related to value-based purchasing arrangements for drug therapies in Medicaid programs, to expand the use of value-based arrangements to drugs covered under Medicaid administered in an inpatient setting, and to make technical changes to pharmaceutical manufacturer report requirements to CMS related to these changes. Equitable Community Access to Pharmacy Services Act (H.R. 1770) - To make permanent certain emergency authorizations from the COVID-19 public health emergency related to pharmacist-provided care for COVID-19, RSV, and influenza (such as testing and immunization) and to allow reimbursement for these services under Medicare Part B. Also to automatically implement these authorizations for future public health emergencies declared under either the Public Health Service Act or the PREP Act.

Client expense: $120,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Access to Prescription Digital Therapeutics Act of 2023 (S. 723/H.R. 1458) - To create a benefit category under Medicare and Medicaid allowing for the coverage of prescription digital therapeutics Medicaid VBPs for Patients Act (H.R. 2666) - To codify the existing Medicaid "multiple best price" rule related to value-based purchasing arrangements for drug therapies in Medicaid programs, to expand the use of value-based arrangements to drugs covered under Medicaid administered in an inpatient setting, and to make technical changes to pharmaceutical manufacturer report requirements to CMS related to these changes. Equitable Community Access to Pharmacy Services Act (H.R. 1770) - To make permanent certain emergency authorizations from the COVID-19 public health emergency related to pharmacist-provided care for COVID-19, RSV, and influenza (such as testing and immunization) and to allow reimbursement for these services under Medicare Part B. Also to automatically implement these authorizations for future public health emergencies declared under either the Public Health Service Act or the PREP Act.

Client expense: $120,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act (H.R. 4818/S.2407) The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)

Client expense: $1,395,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Issues related to prescription drug pricing and value Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax Issues related to Intellectual Property Issues related to Inflation Reduction Act The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)

Client expense: $1,395,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 4189/S.2016, CONNECT for Health Act of 2023 H.R. 4093, Remote Opioid Monitoring Act of 2023 H.R. 824, Telehealth Benefit Expansion for Workers Act of 2023 H.R.1843/S.1001, Telehealth Expansion Act of 2023 H.R. 3875, Expanded Telehealth Access Act H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023 H.R. 7623, Telehealth Modernization Act of 2024 General issues related to federal regulation of health technology - artificial intelligence, digital therapeutics

Client expense: $1,020,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE